Form 4: Stoke Therapeutics Director, Adrian Krainer, Granted Stock Options

Director Adrian Krainer of Stoke Therapeutics, Inc. was granted stock options on June 5, 2024, according to a Form 4 filing with the SEC.

Summary

• Adrian R. Krainer, a director of Stoke Therapeutics, Inc., was granted stock options on June 5, 2024.
• The options, representing the right to buy 7,639 shares of common stock at an exercise price of $16.41, vest on the earlier of June 5, 2025, or the date of the company's next annual meeting, contingent upon continued service.
• A Form 4 filing was submitted to the SEC on June 7, 2024, reporting this transaction.
• Krainer also has a Limited Power of Attorney designating Edward M. Kaye, Jonathan Allan, and Thomas Leggett as Attorneys-in-Fact to execute Forms 3, 4, and 5 on his behalf.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a common practice and generally viewed as a positive sign of aligning management interests with shareholders. There are no negative indicators in the document.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service to the company.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the stock option grant suggests an expectation of continued service and alignment of interests.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of one year or until the next annual meeting is fairly typical.
• Comparing the number of shares granted and the exercise price to similar companies would require further analysis of Stoke Therapeutics' compensation policies and market capitalization.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, aligning the director's interests with the company's long-term success.
• The director is incentivized to contribute to the company's growth and profitability to increase the value of their stock options.

Key Dates